ClinicalTrials.gov
ClinicalTrials.gov Menu

Prevalence and Type Distribution of Human Papillomavirus (HPV) in Tanzanian Men

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00932009
Recruitment Status : Completed
First Posted : July 2, 2009
Last Update Posted : August 11, 2015
Sponsor:
Collaborator:
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Susanne Kruger Kjaer, Danish Cancer Society

Brief Summary:
The purpose of this study is to determine the prevalence and type distribution of genital human papillomavirus (HPV) infection in Tanzanian men.

Condition or disease
Human Papillomavirus Infection

  Show Detailed Description

Study Type : Observational
Actual Enrollment : 1933 participants
Observational Model: Ecologic or Community
Time Perspective: Cross-Sectional
Official Title: Prevalence and Type Distribution of Genital Human Papillomavirus (HPV) in Tanzanian Men
Study Start Date : March 2009
Actual Primary Completion Date : August 2009
Actual Study Completion Date : December 2009

Resource links provided by the National Library of Medicine


Group/Cohort
Human papillomavirus
Tanzanian men with HPV and Tanzanian men without



Primary Outcome Measures :
  1. HPV infection [ Time Frame: At enrollment ]

Secondary Outcome Measures :
  1. HIV infection [ Time Frame: At enrollment ]

Biospecimen Retention:   Samples With DNA
cell scrapes from penis


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Tanzanian men from an urban setting (Dar es Sallam)(factories, University, college)and men from an rural setting (Muhesa, Mwanga, Bagamoyo)
Criteria

Inclusion Criteria:

  • men who are able to understand the information about the study (in writing or oral)

Exclusion Criteria:


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00932009


Locations
Denmark
Inst. of Cancer Epidemiology, Danish Cancer Society
Copenhagen, Denmark, DK-2100
Sponsors and Collaborators
Danish Cancer Society
Merck Sharp & Dohme Corp.
Investigators
Principal Investigator: Susanne K. Kjaer, Professor MD Inst. of Cancer Epidemiology,Danish Cancer Society

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Susanne Kruger Kjaer, Professor, Danish Cancer Society
ClinicalTrials.gov Identifier: NCT00932009     History of Changes
Other Study ID Numbers: HPV IISP #36113
First Posted: July 2, 2009    Key Record Dates
Last Update Posted: August 11, 2015
Last Verified: August 2015

Keywords provided by Susanne Kruger Kjaer, Danish Cancer Society:
Human papillomavirus infection
Tanzanian men
Prevalence

Additional relevant MeSH terms:
Papillomavirus Infections
DNA Virus Infections
Virus Diseases
Tumor Virus Infections